Ambroxol
- Generic Name
- Ambroxol
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Br2N2O
- CAS Number
- 18683-91-5
- Unique Ingredient Identifier
- 200168S0CL
- Background
Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract which play an important role in the body’s natural defence mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.
- Indication
Ambroxol is indicated for secretolytic therapy in bronchoplmonary disease with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient's breathing.
- Associated Therapies
- Airway secretion clearance therapy
An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III
- Conditions
- Sanfilippo SyndromeMPS3
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Ozlem Goker-Alpan
- Target Recruit Count
- 10
- Registration Number
- NCT06614894
- Locations
- 🇺🇸
Lysosomal & Rare Disorders Research & Treatment Center, Inc., Fairfax, Virginia, United States
High-Dose Ambroxol in GBA1-Related Parkinson
- Conditions
- Parkinson DiseaseGBA Gene Mutation
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Agyany Pharma LTD
- Target Recruit Count
- 40
- Registration Number
- NCT06193421
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-09-07
- Target Recruit Count
- 50
- Registration Number
- NCT05959850
- Locations
- 🇦🇺
Concord Repatriation General Hospital, Sydney, New South Wales, Australia
🇦🇺Launceston General Hospital, Launceston, Tasmania, Australia
🇦🇺Brain and Mind Centre, Sydney, New South Wales, Australia
GRoningen Early-PD Ambroxol Treatment
- Conditions
- ParkinsonParkinson Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 80
- Registration Number
- NCT05830396
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Ambroxol to Slow Progression in Parkinson Disease
- Conditions
- Parkinson Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- University College, London
- Target Recruit Count
- 330
- Registration Number
- NCT05778617
- Locations
- 🇬🇧
University Hospitals Birmingham, Birmingham, United Kingdom
🇬🇧Southmead Hospital Bristol, Bristol, United Kingdom
🇬🇧Addenbrookes NHS Trust, Cambridge, United Kingdom
Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients
- Conditions
- Severe PneumoniaCommunity-acquired PneumoniaHospital-acquired PneumoniaCritical Illness
- Interventions
- Other: Standard Therapy
- First Posted Date
- 2022-12-23
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- National University of Malaysia
- Target Recruit Count
- 32
- Registration Number
- NCT05663905
- Locations
- 🇲🇾
Hospital Canselor Tuanku Muhriz UKM (HCTM), Cheras, Kuala Lumpur, Malaysia
Effect of Ambroxol in Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Neuropathy Peripheral
- Interventions
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 80
- Registration Number
- NCT05558878
- Locations
- 🇪🇬
Ain Shams university Hospital, Cairo, Egypt
Ambroxol as a Disease-modifying Treatment in GBA-PD
- Conditions
- Parkinson DiseaseGBA Gene Mutation
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Target Recruit Count
- 65
- Registration Number
- NCT05287503
- Locations
- 🇮🇹
University of Campania "Luigi Vanvitelli", Naples, Italy
🇮🇹IRCCS National Neurological Institute "C. Mondino" Foundation, Pavia, Italy
🇮🇹Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia
- Conditions
- Community-acquired Pneumonia
- Interventions
- Drug: Other oral mucolytic drugsDrug: Eucalyptol, Limonene and Pinene Enteric Soft Capsule
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Beijing Grand Johamu Pharmaceutical Company, Ltd.
- Target Recruit Count
- 10000
- Registration Number
- NCT05002192
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
🇨🇳Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Helse Fonna
- Target Recruit Count
- 180
- Registration Number
- NCT04588285
- Locations
- 🇳🇴
Helse Fonna, Haugesund, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.